Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Relationship between two year PSA nadir and biochemical recurrence in prostate cancer patients treated with iodine-125 brachytherap.

Franca CA, Vieira SL, Carvalho AC, Bernabe AJ, Penna AB.

Radiol Bras. 2014 Mar-Apr;47(2):89-93. doi: 10.1590/S0100-39842014000200010.

2.

Current approaches, challenges and future directions for monitoring treatment response in prostate cancer.

Wallace TJ, Torre T, Grob M, Yu J, Avital I, BrĂ¼cher B, Stojadinovic A, Man YG.

J Cancer. 2014 Jan 1;5(1):3-24. doi: 10.7150/jca.7709. Review.

3.

The role of metabolic imaging in radiation therapy of prostate cancer.

Zhang VY, Westphalen A, Delos Santos L, Tabatabai ZL, Shinohara K, Vigneron DB, Kurhanewicz J.

NMR Biomed. 2014 Jan;27(1):100-11. doi: 10.1002/nbm.3007. Epub 2013 Aug 12. Review.

4.

A Review on the Clinical Utility of PSA in Cancer Prostate.

Adhyam M, Gupta AK.

Indian J Surg Oncol. 2012 Jun;3(2):120-9. doi: 10.1007/s13193-012-0142-6. Epub 2012 Mar 3.

5.

PSA Doubling Time Predicts for the Development of Distant Metastases for Patients Who Fail 3DCRT Or IMRT Using the Phoenix Definition.

Klayton TL, Ruth K, Buyyounouski MK, Uzzo RG, Wong YN, Chen DY, Sobczak M, Peter R, Horwitz EM.

Pract Radiat Oncol. 2011;1(4):235-242.

6.

The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up.

Antonarakis ES, Feng Z, Trock BJ, Humphreys EB, Carducci MA, Partin AW, Walsh PC, Eisenberger MA.

BJU Int. 2012 Jan;109(1):32-9. doi: 10.1111/j.1464-410X.2011.10422.x. Epub 2011 Jul 20.

7.

Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database.

Antonarakis ES, Chen Y, Elsamanoudi SI, Brassell SA, Da Rocha MV, Eisenberger MA, McLeod DG.

BJU Int. 2011 Aug;108(3):378-85. doi: 10.1111/j.1464-410X.2010.09878.x. Epub 2010 Nov 23.

8.

Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial.

Ray ME, Bae K, Hussain MH, Hanks GE, Shipley WU, Sandler HM.

J Natl Cancer Inst. 2009 Feb 18;101(4):228-36. doi: 10.1093/jnci/djn489. Epub 2009 Feb 10.

9.

Determinants of change in prostate-specific antigen over time and its association with recurrence after external beam radiation therapy for prostate cancer in five large cohorts.

Proust-Lima C, Taylor JM, Williams SG, Ankerst DP, Liu N, Kestin LL, Bae K, Sandler HM.

Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):782-91. doi: 10.1016/j.ijrobp.2008.01.056.

10.

How can men destined for biochemical failure after androgen deprivation and radiotherapy be identified earlier?

D'Ambrosio DJ, Ruth K, Horwitz EM, Uzzo RG, Pollack A, Buyyounouski MK.

Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1487-91. doi: 10.1016/j.ijrobp.2007.08.057. Epub 2007 Dec 31.

11.

Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death.

Alcantara P, Hanlon A, Buyyounouski MK, Horwitz EM, Pollack A.

Cancer. 2007 Jan 1;109(1):41-7.

Supplemental Content

Support Center